Navigation Links
Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
Date:3/12/2008

TSX: BMR

TORONTO, March 12 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2007 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2007, the Company achieved the following steps in preparation for the upcoming multi-center Phase III trial and subsequent planned commercialization for its lead drug Neuradiab, a treatment for glioblastoma multiforme, the most deadly form of brain cancer:

- Completed development and validation of cGMP manufacturing processes

of the Neuradiab drug substance (antibody component) and final drug

product (radiolabeled antibody).

- Conducted pre-Phase III meetings with the U.S. Food and Drug

Administration (FDA) regarding the protocol and design of the Phase

III trial as well as the drug manufacturing processes.

- Entered formal contracting and approval processes with more than 30

U.S. clinical trial sites, in line with previously stated site

recruitment goals.

- Prepared and submitted the Company's drug manufacturing data package

to the FDA, subsequent to the end of the fiscal year. The submission

is currently under review. After completion of the review and

satisfactory resolution of any further requests of the FDA, if any,

Bradmer will submit a clinical update to its Investigational New Drug

(IND) application and proceed with the launch of the planned Phase

III trial.

"We have made significant progress toward the initiation of our planned multi-center Phase III trial of Neuradiab by focusing specifically on reducing risk in the critical areas of manufacturing, regulatory and clinical operations," said Alan M. Ezrin, Ph.D
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Notice of Bradmer Pharmaceuticals Conference Call
2. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
3. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
4. Bradmer announces additions to Scientific Advisory Board
5. Bradmer Medical Isotope Supply For Phase III Trial Secure
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer provides Phase III Neuradiab trial update and guidance
8. Bradmer announces management changes
9. NHP Announces Management Promotions
10. WellPoint Announces Appearances at Upcoming Conferences
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Lehman Brothers Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Becker's Hospital Review has published ... Health Systems With Great Oncology Programs." Organizations on this ... quality patient care, cancer outcomes and research. , The ... based on rankings and awards they have received from ... considered as part of the criteria for inclusion on ...
(Date:7/24/2014)... European Omega 3 & Structured Lipids Market report defines and ... with analysis and forecast of revenue. The market is estimated ... million by 2018, at a CAGR of 6.7% from 2013 ... omega 3 & structured lipids market report, to get an ... glimpse of the segmentation of the European market, and is ...
(Date:7/24/2014)... European air and missile defense radar market is estimated to ... a CAGR of 8.06%, to reach $2.07 billion by 2020. ... spenders in the region with a number of indigenous programs. ... (MEADS) program, which has been co-developed by Germany, the U.S., ... air and missile defense radar market report, to get an ...
(Date:7/24/2014)... to the protein p53 refers to cancer biology, and ... have been described in detail. Furthermore, also in cancer ... pathways of tumour cells in order to block their ... The most innovative research on p53 attempts to unveil ... nutrients in healthy cells. Recent studies with cell cultures ...
(Date:7/24/2014)... a way the malaria parasite becomes resistant to ... School of Medicine in St. Louis, also is ... and tuberculosis. , The study appears July 24 ... including the parasite that causes malaria, make a ... roles in keeping organisms healthy, whether plants, animals ...
Breaking Medicine News(10 mins):Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3
... , , , , , , ... Medical,International Limited (NYSE: MR ), a leading developer, ... at its annual general meeting of shareholders held in Hong ... the meeting, Mindray Medical International,s shareholders approved the,re-election of directors ...
... causes more pain than vodka, study finds , FRIDAY, Dec. ... a common indulgence -- and nasty hangovers a common consequence. ... lighter-colored beverages, they might feel a little better the next ... contain more toxic properties that provoke more painful hangovers than ...
... , , , NEWPORT BEACH, Calif., Dec. 18 ... announced today that it has given notice that it is ... Cumulative Convertible Preferred Stock ("Series B Preferred Stock") (NHP-PB - ... price per share of $103.875 plus an amount equal to ...
... thoughts may help explain interpersonal problems , FRIDAY, Dec. ... are less active than expected when they,re engaged in ... difficulties, say British researchers. , Using functional MRI, they ... whom had autism, while they were asked questions about ...
... CentraCare president is new chair , ST. PAUL, Minn., Dec. ... systems, recently elected or re-elected the following members to its board for ... Chair - Terence Pladson, M.D., president, CentraCare Health System, ... CEO, Queen of Peace Hospital, New Prague, Secretary/treasurer - ...
... , , HOUSTON, Dec. 18 ... largest provider of deathcare products and services in North America, ... has extended the expiry time of its offer (the "Offer") ... and outstanding common shares in the capital of Keystone North ...
Cached Medicine News:Health News:Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 2Health News:For a Lighter Hangover, Avoid Darker Drinks 2Health News:For a Lighter Hangover, Avoid Darker Drinks 3Health News:For a Lighter Hangover, Avoid Darker Drinks 4Health News:Nationwide Health Properties, Inc. Announces the Redemption of All Outstanding Shares of 7.75% Series B Cumulative Convertible Preferred Stock 2Health News:Brain Imaging Sheds Light on Social Woes Related to Autism 2Health News:Minnesota Hospital Association Elects, Re-Elects Members to Board 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 2Health News:Service Corporation International Extends Offer for Keystone North America Inc. 3
(Date:7/24/2014)... 2014  To help health care organizations better ... impact patient care and the bottom line, Novation ... "Innovations in Cardiovascular Devices."  The ... details on promising new technologies that can help ... these options impact the supply chain.   According to ...
(Date:7/24/2014)... , July 24, 2014  Blueprint Medicines (Blueprint), a ... defined cancer patients, today announced the appointment of ... Albers joins Blueprint from Algeta ASA, where he served ... to the acquisition by Bayer. Mr. Albers succeeds ... and Partner at Third Rock Ventures, who will remain ...
(Date:7/24/2014)... 2014  Bayer HealthCare today announced positive results ... 15% foam formulation of its compound azelaic acid ... and pustules of rosacea. An AzA foam formulation ... currently available AzA gel formulation. Papulopustular rosacea is ... pustules) as well as erythema (redness) on the ...
Breaking Medicine Technology:New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3
... YORK, Nov. 5 Immtech Pharmaceuticals,Inc. (Amex: ... $5.1 million from a,scientific consortium led by the ... received funds from The Bill & Melinda Gates ... African sleeping,sickness (trypanosomiasis) and leishmania. This grant is ...
... experts from the,Alzheimer,s Foundation of America (AFA) today ... in light of research,indicating that cases of mild ... that early diagnosis can lead to appropriate treatment ... chief executive officer, and J. Wesson Ashford,M.D., Ph.D., ...
Cached Medicine Technology:Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 2Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 3Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 2Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 3Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 4
... throughput reading of entire racks. Its scanner-based image ... and reads in approximately 10 seconds per rack. ... and a list of ActiveX controls is provided ... includes a USB HP Scanner and software. Compatible ...
... with powder-coated steel legs. Height ... in hundreds of sizes and ... light fixtures and ionizing equipment. ... custom building to meet special ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
Medicine Products: